Speaker
Description
Background: Following the 2022 European Council recommendation to evaluate organised, risk-stratified prostate cancer (PCa) screening, the PRAISE-U (PRostate cancer Awareness and Initiative for Screening in the European Union) project implemented a risk-stratified screening protocol across five pilot sites. We assessed the conditions required to translate these pilots into sustainable population-based programmes.
Methods: We conducted a comparative scalability assessment across the five PRAISE-U pilot sites using a modified ten-domain Intervention Scalability Assessment Tool (ISAT), supplemented by TAPIC (Transparency, Accountability, Participation, Integrity, Capacity)-based governance analysis. Evidence was triangulated from the pre-implementation capacity and readiness assessments, facility assessments, multi-level stakeholder consultations and Collaborative User Boards (CUBs), programme key performance indicators, first-round clinical effectiveness outputs, and site-specific economic evaluations. Each domain was scored on a 0-3 readiness scale by consensus by the Scalability team.
Findings: Across the five pilots, 90,245 men were invited and 15,174 participated (site range 7.1-43%). Compliance with each diagnostic step after Prostate-Specific Antigen (PSA) testing was high, and first-level risk stratification reduced Magnetic Resonance Imaging (MRI) referrals by 48% (range 30-58%). Problem definition was consistently strong, whereas intervention specification was moderate across most sites and lower in Lower Silesia, indicating that the clinical pathway requires further standardisation and context-specific adaptation before wider transfer across health systems. The weakest domains across sites were intervention costs, evidence of effectiveness, implementation infrastructure, and sustainability. Descriptive means of the ten ISAT domains were 2.53 (Galicia), 2.49 (Lithuania), 2.47 (Manresa), 2.03 (Ireland) and 1.99 (Lower Silesia); TAPIC governance composites ranged from 1.6 (Lower Silesia) to 2.1 (Lithuania).
Interpretation: The core clinical sequence was feasible across contrasting health systems, although wider implementation requires context-specific adaptation, sustainable financing, standardisation, quality assurance, accountable governance, and integration of opportunistic PSA testing.
Funding This project has received funding from the EU4Health programme under grant agreement 101101217, co-funded by the European Union.
Keywords: Prostate cancer; Screening; Scalability; ISAT; TAPIC; Implementation research; PRAISE-U